Tsubaki Premium EX Dandruff Care & Repair Treatment

TSUBAKI Premium EX Dandruff Care & Repair Treatment is a scalp and hair repair-focused treatment that helps hydrates the scalp, repairs damaged hair, and supports dandruff control through Japanese Scalp Spa formula and Camellia Oil Force ingredient. 

TSUBAKI Premium EX Dandruff Care & Repair is a beauty-first anti-dandruff shampoo & treatment that delivers an instant scalp refresh with 72hours itch relief’ and flake protection. Formulated using Japanese Scalp Spa Formula and Tsubaki’s Signature Camellia Oil Force to help tackle three major scalp concerns and provide scalp care maintenance for a Japan salon-quality hair at home. 

Three major scalp concerns mentioned above includes

• REDUCES DANDRUFF & PROTECTS AGAINST FLAKES  

72 hours dandruff protection* Get clear scalp without visible flakes instantly*. Formulated with Piroctone Olamine, known to help control the fungus that causes dandruff.

• ITCH RELIEF' & IMPROVES SCALP MICROBIOME^^

Long-lasting itch relief for up to 72 hours*. Infused with Menthol to provide a refreshing cooling sensation that helps relieve itchiness', and Aloe Vera known to help soothe"" scalp.

Saccharide Isomerate helps reduce excess sebum and dryness-related irritation.

• OIL CONTROL BALANCE & MOISTURISING EFFECT

Powered by Tsubaki’s signature ingredient: Camellia Oil Force to deeply moisturise, repair damage, reduce frizz and breakage, and hydrate the scalp for healthier hair and scalp.

Enhanced with Double Hyaluronic Acid and amino acids, it helps replenish moisture levels to keep the hair comfortably hydrated.

Delivers up to 72 hours of long-lasting moisturising effect^, while effectively controlling excess oil for up to 72 hours**

Fragrance of fresh floral camellia

Disclaimers:

*Based on clinical test ,20 respondents China, May 2025.

**Based on Clinical human test, 21 respondents, China. May-Jul. 2025.

'Due to dryness

""By moisturising effect

^Based on instrumental evaluation on hair tress, China, Jun.2025

^^Based on Clinical human test, 22 respondents, China. May-Jul. 2025.